3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
24
Neoplasm Metastasis
7
Neoplasms
5
Prostate Cancer Metastatic
4
Carcinoma, Transitional Cell
4
Recurrence
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Carcinoma, Squamous Cell
2
Carcinoma, Non-Small-Cell Lung
2
Solid Cancer
1
Small Cell Lung Carcinoma
1
Penile Neoplasms
1
Ovarian Neoplasms
1
Nonseminomatous germ cell tumor
1
Neoplastic Cells, Circulating
1
Metastatic Castration-resistant Prostate Cancer
1
Malignant Solid Tumor - Malignant Nervous System Neoplasm
1
Lymphadenopathy
1
Liposarcoma
1
Hormone Refractory Prostate Cancer
1
Head and Neck Neoplasms
1
Glioblastoma
1
Breast Neoplasms
1
Bone Metastatic Prostate Cancer
1
Advanced Solid Tumor
1
Interventions
Blood Specimen Collection
13
Reverse Transcriptase Polymerase Chain Reaction
7
Flow Cytometry
7
Surgical Procedures, Operative
3
Pirinitramide
2
Morphine
2
Bevacizumab
2
ribociclib
1
lanreotide
1
jinfukang
1
eribulin
1
cabazitaxel
1
Zoledronic Acid
1
Vinorelbine
1
Trastuzumab
1
Thiotepa
1
Taxes
1
Stem Cell Transplantation
1
Standard of Care
1
Spinal Puncture
1
Sorafenib
1
Radiofrequency Ablation
1
Propofol
1
Pemetrexed
1
Octreotide
1
Letrozole
1
Lapatinib
1
Injections, Epidural
1
Injections
1
Hematologic Tests
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplastic Cells, Circulating
×
cabazitaxel
×
Clear all
NCT03101046
2022-02-10
TACTIK
UNICANCER
Phase 2
Completed
40 enrolled